| 1 |
Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification[J]．Endocr Relat Cancer, 2001, 8(1):11-31.
|
| 2 |
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network[J]．Nat Rev Mol Cell Biol, 2001, 2(2):127-137.
|
| 3 |
Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J]．Science，2004, 305(5687):1163-1167.
|
| 4 |
Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma[J]．J Thorac Oncol, 2006, 1(5):413-416.
|
| 5 |
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]．Lancet Oncol, 2012, 13(3):239-246.
|
| 6 |
Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase Ⅲ study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J]．J Thorac Oncol，2012, 7(1):115-121.
|
| 7 |
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]．Lancet Oncol, 2010, 11(2):121-128.
|
| 8 |
Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study[J]．Lancet Oncol，2012, 13(1):33-42.
|
| 9 |
Tamura K, Fukuoka M. Molecular target-based cancer therapy: tyrosine kinase inhibitors[J]．Int J Clin Oncol, 2003, 8(4):207-211.
|
| 10 |
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]．Lancet, 2005, 366(9496):1527-1537.
|
| 11 |
Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study[J]．J Thorac Oncol, 2006, 1(8):847-855.
|
| 12 |
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]．N Engl J Med，2005, 353(2):123-132.
|
| 13 |
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase Ⅲ trial[J]．Lancet, 2008, 372(9652):1809-1818.
|
| 14 |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]．N Engl J Med, 2009, 361(10):947-957.
|
| 15 |
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]．N Engl J Med, 2010, 362(25):2380-2388.
|
| 16 |
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]．Lancet Oncol，2011, 12(8):735-742.
|
| 17 |
Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]．J Clin Oncol, 2013, 31(27):3327-3334.
|
| 18 |
Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]．Lancet Oncol，2014, 15(2):213-222.
|
| 19 |
Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]．J Clin Oncol, 2013, 31(27):3320-3326.
|
| 20 |
Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]．J Thorac Oncol, 2011, 6(3):569-575.
|
| 21 |
Li N, Ou W, Ye X, et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J]．Ann Surg Oncol, 2014, 21(6):2091-2096.
|
| 22 |
Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-ⅢA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase Ⅲ Trial[J]．J Clin Oncol, 2015, 33(34):4007-4014.
|
| 23 |
Lampaki S, Lazaridis G, Zarogoulidis K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer[J]．J Cancer, 2015, 6(6):568-574.
|
| 24 |
Huang Q, Li J, Sun Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant eatment for operable non-small cell lung cancer by a meta-analysis[J]．Chest, 2016, 149(6):1384-1392.
|
| 25 |
Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J]．J Clin Oncol，2005, 23(25):5892-5899.
|
| 26 |
Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial[J]．J Clin Oncol, 2007, 25(12):1545-1552.
|
| 27 |
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]．J Clin Oncol，2004, 22(5):785-794.
|
| 28 |
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]．J Clin Oncol，2004, 22(5):777-784.
|
| 29 |
Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial[J]．Lancet Oncol, 2013, 14(8):777-786.
|
| 30 |
Sugawara S, Oizumi S, Minato K, et al. Randomized phase Ⅱ study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902[J]．Ann Oncol, 2015, 26(5):888-894.
|
| 31 |
Cheng Y, Murakami H, Yang PC, et al. Randomized phase Ⅱ trial of Gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations[J]．J Clin Oncol, 2016，34(27):3258-3266.
|
| 32 |
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]．Lancet Oncol, 2014, 15(11):1236-1244.
|
| 33 |
Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]．N Engl J Med, 2015, 372(18):1689-1699.
|
| 34 |
Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer[J]．N Engl J Med, 2015, 372(18):1700-1709.
|
| 35 |
Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer[J]．Clin Cancer Res, 2012, 18(6):1663-1671.
|
| 36 |
Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer[J]．Mol Cancer Ther, 2012, 11(10):2149-2157.
|
| 37 |
Gou LY, Li AN, Yang JJ, et al. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer[J]. Oncotarget, 2016，7(32):51311-51319.
|
| 38 |
Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016[J]．J Thorac Oncol, 2016, 11(7):946-963.
|
| 39 |
Hata A, Katakami N, Yoshioka H, et al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases[J]．Anticancer Res, 2015, 35(2):1025-1031.
|
| 40 |
Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations[J]. J Thorac Oncol，2016，11(11):1962-1969.
|